Simple Summary The current meta-analysis highlighted that proton pump inhibitors (PPIs)
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors (…

… Our study finds that Proton Pump Inhibitors worsen the outcomes of overall survival and … to
use proton pump inhibitors more judiciously in patients with Non-Small Cell Lung Carcinoma. …

… The cancer with the highest morbidity and mortality is lung cancer. Non-small cell lung
cancer (NSCLC) accounts for a high proportion of all lung cancers (up to 85–90%). NSCLC …

… We used ICD-O-3 code C33–C34 to identify patients with lung cancer in the TCR database
… with EGFR mutations, no prior cancer record before lung cancer diagnosis, and receiving first-…

… Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal absorption of …
We investigated the effects of erlotinib coadministration with proton pump inhibitors (PPIs) and …

… of proton pump inhibitors (PPIs) and ICIs, and poor prognosis in patients with nonsmall …
lung cancer (NSCLC). We conducted a cohort study using a completely enumerated lung cancer …

Background Proton pump inhibitors (PPIs) are commonly used concomitant to cancer
treatment and they induce gut microbiota changes. It is increasingly apparent that gut dysbiosis …

… Use of antibiotics or proton pump inhibitors in patients with non-small cell lung cancer is …
Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, …

… lung cancer Using the NHIRD, we identified patients older than 18 years of age with lung
cancer … of NHIRD, and pathological confirmation of lung cancer is required to apply this registry. …

… lung cancer (NSCLC) patients treated with ICB and analyzed 80 fecal samples of patients
with lung cancer … shown to improve the ICB efficacy in lung cancer. Thus, we investigated how …